Concert Pharma (CNCE) Reports Q2 EPS of $0.16
Tweet
Share
E-mailGet Alerts CNCE Hot Sheet
Join SI Premium – FREE
Concert Pharma (NASDAQ: CNCE) reported Q2 EPS of $0.16, versus ($0.41) reported last year. Revenue for the quarter came in at $32 million, versus $6.4 million reported last year.
For earnings history and earnings-related data on Concert Pharma (CNCE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
- Traws Pharma (TRAW) Tops Q2 EPS by 27c
- Citius Pharmaceuticals (CTXR) Misses Q3 EPS by 37c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
